Tocilizumab Induces Rapid, Sustained Improvement of Inflammatory Markers in COVID-19, With Clinical Improvement in Most Patients.

Authors	Scott J Morin, Chinmay Jani, Arashdeep Rupal, Harpreet Singh, Daniel Bourque, Robert C Colgrove
Journal	American journal of therapeutics (Am J Ther) Vol. 28 Issue 5 Pg. e592-e596 (07 05 2021) ISSN: 1536-3686 [Electronic] United States
PMID	34264890 (Publication Type: Letter)
Chemical References	Antibodies, Monoclonal, Humanized tocilizumab
Topics	Antibodies, Monoclonal, Humanized Humans SARS-CoV-2 COVID-19 Drug Treatment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!